Cancer
Malignant Prostate Neoplasm
CI-CAN-00005927Explore in graph →
Top-level1,377 active trials24 approved drugs58 evidence items
- NCIt
- C7378
- ICD-10
- C61
- DOID
- 10283
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00005927Explore in graph →
Clinical trials
5,979 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (730)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01688492 | Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer | active not recruiting | Phase 1 / Phase 2 | 54 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT01737242 | UK Genetic Prostate Cancer Study: Epidemiology and Molecular Genetics Studies(UKGPCS) | active not recruiting | — | 23,826 | Institute of Cancer Research, United Kingdom |
| 1 |
| Aug 12, 2026 |
| clinicaltrials |
| NCT04007770 | Acupuncture Pilot Study for Cancer-related Cognitive Function | active not recruiting | Phase 2 | 48 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT04126070 | Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors | active not recruiting | Phase 2 | 47 | Xiao X. Wei, MDOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT01786265 | Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer | active not recruiting | Phase 2 | 310 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT03575832 | Watchful Living in Improving Quality of Life in Participants With Localized Prostate Cancer on Active Surveillance and Their Partners | active not recruiting | N/A | 64 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT02949284 | Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery | active not recruiting | Phase 2 | 90 | Rutgers, The State University of New JerseyOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT03706365 | A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer(CYCLONE 2) | active not recruiting | Phase 2 / Phase 3 | 393 | Eli Lilly and CompanyINDUSTRY | 11 | Aug 7, 2026 | clinicaltrials |
| NCT05513443 | Prostate Cancer IRE Study (PRIS)(PRIS) | active not recruiting | N/A | 184 | Karolinska InstitutetOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT06305598 | Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer | active not recruiting | Phase 1 | 3 | Roswell Park Cancer InstituteOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07038369 | A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations | active not recruiting | Phase 1 | 134 | Atavistik Bio, IncINDUSTRY | 4 | Aug 7, 2026 | clinicaltrials |
| NCT03419234 | Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel | active not recruiting | Phase 2 | 223 | ECOG-ACRIN Cancer Research GroupNETWORK | 2 | Aug 6, 2026 | clinicaltrials |
| NCT04766190 | DISCO: A Patient Intervention to Reduce the Financial Burden of Cancer(DISCO) | active not recruiting | N/A | 254 | Lauren HamelOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT04030338 | Prostate-Specific Membrane Antigen (PSMA) PET Scans in People Prostate Cancer | active not recruiting | — | 58 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT03531099 | Phase 3, Multicenter, Randomized Study, Evaluating the Efficacy and Tolerability of Focused HIFU (High Intensity Focused Ultrasound) Therapy Compared to Active Surveillance in Patients With Significant Low Risk Prostate Cancer(HIFUSA) | active not recruiting | Phase 3 | 108 | Hospices Civils de LyonOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT06380660 | Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 298 | Acerand Therapeutics (Shanghai) LimitedINDUSTRY | 1 | Aug 4, 2026 | clinicaltrials |
| NCT04197141 | Hypofractionated Whole-Pelvis Radiotherapy (WPRT) vs Conventionally-Fractionated WPRT in Prostate Cancer(HOPE) | active not recruiting | Phase 2 | 58 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT00967863 | Radiation Therapy in Treating Patients Receiving Hormone Therapy for Prostate Cancer (GETUG-AFU 18) | active not recruiting | N/A | 500 | UNICANCEROTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT02893917 | Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer | active not recruiting | Phase 2 | 90 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT03517969 | M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | active not recruiting | Phase 2 | 73 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT05828082 | Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer | active not recruiting | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT04879940 | Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization | active not recruiting | Phase 2 | 17 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT03246347 | A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer | active not recruiting | Phase 2 | 40 | Wake Forest University Health SciencesOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT05345444 | Radiation Therapy and IRreversible Electroporation for Intermediate Risk Prostate Cancer (RTIRE)(RTIRE) | active not recruiting | N/A | 48 | Weill Medical College of Cornell UniversityOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT04484818 | Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study | active not recruiting | Phase 3 | 27 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jul 28, 2026 | clinicaltrials |
| NCT05844761 | Real-time Motion Management During Prostate and Lung Radiotherapy(REMIND) | active not recruiting | N/A | 132 | Region SkaneOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT06441994 | Clinical Trial of Targeted Alpha Therapy Using [At-211]PSMA-5 for Prostate Cancer(Alpha-PS1) | active not recruiting | Phase 1 | 15 | Osaka UniversityOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT00002540 | Screening for Prostate Cancer in Older Patients (PLCO Screening Trial) | active not recruiting | N/A | 76,685 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2026 | clinicaltrials |
| NCT03456843 | Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer | active not recruiting | Phase 2 | 190 | Yale UniversityOTHER | 6 | Jul 24, 2026 | clinicaltrials |
| NCT03957252 | Validation of ClarityDX Prostate as a Reflex Test to Refine the Prediction of Clinically-significant Prostate Cancer(APCaRI-05) | active not recruiting | — | 2,800 | NanosticsINDUSTRY | 2 | Jul 24, 2026 | clinicaltrials |
| NCT06014255 | Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer(HEAT) | active not recruiting | Phase 2 | 219 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT02303327 | Comparative Study of Radiotherapy Treatments to Treat High Risk Prostate Cancer Patients | active not recruiting | Phase 3 | 307 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT04471974 | ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer | active not recruiting | Phase 2 | 61 | Rahul AggarwalOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06228404 | Clinical Study of Safety and Efficacy of Enhanced PSMA CAR- T in Refractory CRPC | active not recruiting | Early Phase 1 | 18 | Shanghai Changzheng HospitalOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06895811 | Clinical Study of Safety and Efficacy of Universal PSMA CAR- T in Refractory CRPC | active not recruiting | Phase 1 | 3 | Shanghai Changzheng HospitalOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT07721532 | Observing the Real-world Non-interventional Study of Abiraterone Acetate Tablets (II) in Treating Chinese Patients With Metastatic Prostate Cancer(prostate) | active not recruiting | — | 3,000 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT01352429 | Mild Hypofractionation With Proton Therapy or IMRT for Intermediate-Risk Prostate Cancer | active not recruiting | — | 303 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT05653063 | ARCHERY - Artificial Intelligence Based Radiotherapy Treatment Planning for Cervical, Head and Neck and Prostate Cancer | active not recruiting | — | 1,029 | University College, LondonOTHER | 4 | Jul 22, 2026 | clinicaltrials |
| NCT04549207 | Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer | active not recruiting | Phase 4 | 240 | Ottawa Hospital Research InstituteOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT05416996 | A Study of Telemedicine Shared Medical Appointments (SMAs) Versus Individual Telemedicine Visits for People With Prostate Cancer | active not recruiting | — | 88 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT06183905 | Multi-parametric Ultrasound Versus Multi-parametric MRI for Prostate Cancer Detection(TRUSVSMPMRI) | active not recruiting | N/A | 635 | Xinhua Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT04915508 | Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy(EXCALIBUR) | active not recruiting | Phase 2 | 165 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT03999151 | Diet and Exercise Interventions Among Men With Prostate Cancer (Prostate 8-II) | active not recruiting | N/A | 204 | University of California, San FranciscoOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT04267887 | Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer | active not recruiting | Phase 2 | 7 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT05169970 | A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer | active not recruiting | Phase 2 | 222 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05842057 | Human Amnion Membrane Allograft and Early Return of Erectile Function After Radical Prostatectomy(HAMMER) | active not recruiting | Phase 2 | 118 | University of MiamiOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT00868803 | Aberrant Gene Expression Prostate Carcinoma | active not recruiting | — | 5,000 | Lahey ClinicOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT02861573 | Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) | active not recruiting | Phase 1 / Phase 2 | 1,200 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jul 13, 2026 | clinicaltrials |
| NCT04748042 | Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON) | active not recruiting | Phase 2 | 21 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 13, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Aug 12, 2026source: clinicaltrials